ClinicalTrials.gg
CompletedNCT01866163Updated Mar 10, 2025Results posted

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

A Phase 3 interventional study of LEO 90100 and Vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
16th of 47
426 · median 200
Started
2013
with 5 others
Phase 3
17 of 47
none open now
Registered
26th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 16th largest by enrollment, is one of 6 that started in 2013, is one of 17 in phase 3, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs
  • Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the Body Surface Area (BSA)
  • An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day 0 (Visit 1)
  • A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)
  • A target lesion of a minimum of 5 cm at its longest axis and preferably not located on the extensor surface on an elbow or knee, scoring at least 1 for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:

    • etanercept - within 4 weeks prior to randomisation
    • adalimumab, infliximab - within 8 weeks prior to randomisation
    • ustekinumab - within 16 weeks prior to randomisation
    • other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer)
  • Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., , retinoids, methotrexate, ciclosporin and other ) within 4 weeks prior to randomisation.
  • Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.
  • PUVA therapy within 4 weeks prior to randomisation.
  • UVB therapy within 2 weeks prior to randomisation.
  • Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation.
  • Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation.
  • Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the trial.
  • Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Previously randomised in this trial or any previously conducted trial of LEO 90100.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
426 participants (actual)

Study arms

  • Experimental
    LEO 90100

    LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)

    Drug: LEO 90100

  • Placebo comparator
    Vehicle

    Aerosol foam vehicle

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Success According to IGA

    Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4. The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe

    Time frame: 4 weeks

Secondary outcomes

  1. m-PASI at Week 4

    The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).

    Time frame: 4 weeks

  2. m-PASI at Week 1

    The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).

    Time frame: 1 week

07

Results

Posted May 9, 2016

Participant flow

First Subject First Visit: 17-Jun-2013 Last Subject Last Visit: 02-Oct-2013

Participant flow — Overall Study
MilestoneLEO 90100Vehicle
Started323103
Completed31399
Not completed104

Outcome measures

PrimaryTreatment Success According to IGA

Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4. The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe

Time frame:
4 weeks
Reported as:
Number · percentage of subjects
Treatment Success According to IGA
percentage of subjectsLEO 90100Vehicle
Treatment Success According to IGA53.34.8
Statistical analysis
  • LEO 90100 vs Vehicle · Mantel Haenszel · p = <0.001 · Odds ratio (or): 30.27 · 95% CI 9.72 to 94.30
Secondarym-PASI at Week 4

The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).

Time frame:
4 weeks
Reported as:
Mean · Scores on a scale
m-PASI at Week 4
Scores on a scaleLEO 90100Vehicle
m-PASI at Week 42.04 (1.74 to 2.35)5.33 (4.79 to 5.86)
Statistical analysis
  • LEO 90100 vs Vehicle · ANOVA · p = <0.001 · Mean difference (final values): -3.28 · 95% CI -3.90 to -2.67
Secondarym-PASI at Week 1

The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI). m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI. The m-PASI score range from 0 (best) to 64.8 (worst).

Time frame:
1 week
Reported as:
Mean · Scores on a scale
m-PASI at Week 1
Scores on a scaleLEO 90100Vehicle
m-PASI at Week 14.66 (4.41 to 4.90)5.93 (5.50 to 6.36)
Statistical analysis
  • LEO 90100 vs Vehicle · ANOVA · p = <0.001 · Mean difference (final values): -1.27 · 95% CI -1.76 to -0.78

Adverse events

Non-serious events are listed at a 0.6% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 90100—2/323 (0.6%)18/323 (5.6%)
Vehicle—0/103 (0%)15/103 (14.6%)
Most frequent serious events
Most frequent serious events
EventLEO 90100Vehicle
Substance induced psychotic disorderPsychiatric disorders1/3230/103
Bipolar disorderPsychiatric disorders1/3230/103
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLEO 90100Vehicle
Application site painGeneral disorders3/3232/103
NasopharyngitisInfections and infestations6/3230/103
DiarrhoeaGastrointestinal disorders2/3231/103
Eye infectionInfections and infestations0/3231/103
Gastroenteritis viralInfections and infestations0/3231/103
Streptococcal infectionInfections and infestations0/3231/103
Application site drynessGeneral disorders0/3231/103
Application site erosionGeneral disorders0/3231/103
Application site erythemaGeneral disorders0/3231/103
Application site oedemaGeneral disorders0/3231/103

Baseline characteristics

Age, Continuous
Age, Continuous(years)LEO 90100VehicleTotal
Mean51.2 ± 13.946.0 ± 13.250.0 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)LEO 90100VehicleTotal
Female11954173
Male20449253
08

Study locations

1 site
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
09

References and documents

Publications

  • Veverka KA, Hansen JB, Yaloumis M, Kircik L, Stein Gold L. Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials. J Drugs Dermatol. 2021 Aug 1;20(8):822-828. doi: 10.36849/JDD.5743. PubMed 34397196 ↗
  • Iversen L, Kurvits M, Snel-Prento AM, Menter A. Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA >/= 3: Post-Hoc Analysis From Three Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Oct;10(5):1111-1120. doi: 10.1007/s13555-020-00419-2. Epub 2020 Aug 12. PubMed 32785881 ↗
  • Stein Gold L, Villumsen J, Rosen M. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis. Dermatol Ther (Heidelb). 2016 Dec;6(4):667-673. doi: 10.1007/s13555-016-0147-0. Epub 2016 Oct 6. PubMed 27714595 ↗
  • Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Osterdal ML, Stein Gold L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015 Dec;14(12):1468-77. PubMed 26659941 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 2 years 7 months after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2013
First posted
May 31, 2013
Start
Jun 2013
Primary completionActual
Oct 2013
CompletionActual
Nov 2013
Results delay requested
Jul 13, 2015
Results first posted
May 9, 2016
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01866163
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 31, 2013
Start date
Jun 2013
Primary completion
Oct 2013
Completion
Nov 2013
Results posted
May 9, 2016
Last update
Mar 10, 2025

Study contacts

Craig Leonardi
principal investigator · Central Dermatology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion